Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max S Topp

Showing results (61-70 of 122) with videos related to

Pageof 13
Sort By:
Blood|March 29, 2011
Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicansClaudia Stuehler, Nina Khanna, Silvia Bozza, et al.
Leukemia|August 19, 2021
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study GroupCarla Damaschin, Helen Goergen, Stefanie Kreissl, et al.
Journal of Cancer Research and Clinical Oncology|February 19, 2022
Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphomaMax S Topp, Herbert Eradat, Axel Florschütz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trialAndreas Engert, Andreas Josting, Heinz Haverkamp, et al.
Blood|October 21, 2015
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatmentGerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, et al.
The Lancet. Oncology|November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2020
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple MyelomaMax S Topp, Johannes Duell, Gerhard Zugmaier, et al.
Blood|April 19, 2015
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphomaAchim Rothe, Stephanie Sasse, Max S Topp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study GroupStephanie Sasse, Helen Goergen, Annette Plütschow, et al.
Blood Advances|October 25, 2019
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemiaNicola Gökbuget, Hagop M Kantarjian, Monika Brüggemann, et al.
Pageof 13

Showing results (61-70 of 122) with videos related to

Sort By:
Pageof 13
Blood|March 29, 2011
Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicansClaudia Stuehler, Nina Khanna, Silvia Bozza, et al.
Leukemia|August 19, 2021
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study GroupCarla Damaschin, Helen Goergen, Stefanie Kreissl, et al.
Journal of Cancer Research and Clinical Oncology|February 19, 2022
Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphomaMax S Topp, Herbert Eradat, Axel Florschütz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trialAndreas Engert, Andreas Josting, Heinz Haverkamp, et al.
Blood|October 21, 2015
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatmentGerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, et al.
The Lancet. Oncology|November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2020
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple MyelomaMax S Topp, Johannes Duell, Gerhard Zugmaier, et al.
Blood|April 19, 2015
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphomaAchim Rothe, Stephanie Sasse, Max S Topp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study GroupStephanie Sasse, Helen Goergen, Annette Plütschow, et al.
Blood Advances|October 25, 2019
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemiaNicola Gökbuget, Hagop M Kantarjian, Monika Brüggemann, et al.
Pageof 13